Public Employees Retirement Association Of Colorado Biotechnology

Public Employees Retirement Association Of Colorado

$25.2 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
BCRX Biocryst Pharmaceuticals Inc	$1.46B	$208,000 0.0% of portfolio	27,713	Q3 2023 Added 212.05%
CLDX Celldex Therapeutics, Inc.	$932M	$197,000 0.0% of portfolio	7,787	Q1 2024 New
GERN Geron Corp	$623M	$194,000 0.0% of portfolio	54,913	Q2 2024 Reduced 38.8%
AUPH Aurinia Pharmaceuticals Inc.	$1.18B	$192,000 0.0% of portfolio	21,360	Q2 2024 Reduced 3.94%
KYMR Kymera Therapeutics, Inc.	$1.62B	$188,000 0.0% of portfolio	4,672	Q2 2024 New
TVTX Travere Therapeutics, Inc.	$1.26B	$188,000 0.0% of portfolio	10,796	Q3 2023 Added 84.36%
SNDX Syndax Pharmaceuticals Inc	$746M	$182,000 0.0% of portfolio	13,746	Q2 2024 Reduced 15.27%
IMVT Immunovant, Inc.	$3.55B	$166,000 0.0% of portfolio	6,698	Q3 2023 Reduced 79.17%
SWTX Spring Works Therapeutics, Inc.	$2.96B	$165,000 0.0% of portfolio	4,575	Q3 2023 Reduced 97.82%
VERA Vera Therapeutics, Inc.	$720M	$157,000 0.0% of portfolio	3,718	Q2 2024 New
BEAM Beam Therapeutics Inc.	$1.37B	$155,000 0.0% of portfolio	6,230	Q3 2023 Added 735.12%
DYN Dyne Therapeutics, Inc.	$593M	$135,000 0.0% of portfolio	5,740	Q2 2024 New
ARDX Ardelyx, Inc.	$762M	$124,000 0.0% of portfolio	24,496	Q2 2024 New
IOVA Iovance Biotherapeutics, Inc.	$562M	$124,000 0.0% of portfolio	16,764	Q4 2020 Reduced 10.36%
RXRX Recursion Pharmaceuticals, Inc.	$1.05B	$116,000 0.0% of portfolio	17,217	Q2 2024 New
NTLA Intellia Therapeutics, Inc.	$613M	$114,000 0.0% of portfolio	9,760	Q3 2023 Reduced 98.47%
RCKT Rocket Pharmaceuticals, Inc.	$574M	$103,000 0.0% of portfolio	8,193	Q3 2023 Reduced 70.58%
TBPH Theravance Biopharma, Inc.	$616M	$102,000 0.0% of portfolio	10,856	Q3 2023 Reduced 74.0%
ARQT Arcutis Biotherapeutics, Inc.	$947M	$92,000 0.0% of portfolio	6,577	Q3 2024 New
PRTA Prothena Corp Public LTD CO	$581M	$91,000 0.0% of portfolio	6,552	Q3 2023 Reduced 28.78%
MRVI Maravai Lifesciences Holdings, Inc.	$310M	$85,000 0.0% of portfolio	15,511	Q3 2023 Added 232.35%
KURA Kura Oncology, Inc.	$472M	$83,000 0.0% of portfolio	9,545	Q2 2024 Reduced 15.49%
VIR Vir Biotechnology, Inc.	$889M	$80,000 0.0% of portfolio	10,862	Q3 2023 Reduced 2.43%
NUVB Nuvation Bio Inc.	$395M	$79,000 0.0% of portfolio	29,841	Q2 2024 Reduced 17.84%
EWTX Edgewise Therapeutics, Inc.	$1.47B	$76,000 0.0% of portfolio	2,849	Q3 2024 New
ADPT Adaptive Biotechnologies Corp	$1.1B	$74,000 0.0% of portfolio	12,322	Q3 2023 Reduced 28.91%
ARVN Arvinas, Inc.	$404M	$68,000 0.0% of portfolio	3,526	Q3 2023 Reduced 76.47%
CDXS Codexis, Inc.	$184M	$65,000 0.0% of portfolio	13,643	Q2 2024 Reduced 3.73%
NVAX Novavax Inc	$548M	$63,000 0.0% of portfolio	7,873	Q3 2023 Reduced 5.37%
PLRX Pliant Therapeutics, Inc.	$71.6M	$58,000 0.0% of portfolio	4,422	Q3 2024 New
SAGE Sage Therapeutics, Inc.	$492M	$49,000 0.0% of portfolio	8,938	Q3 2023 Reduced 45.43%
RGNX Regenxbio Inc.	$338M	$47,000 0.0% of portfolio	6,040	Q3 2023 Reduced 94.68%
RVNC Revance Therapeutics, Inc.	$212M	$46,000 0.0% of portfolio	15,252	Q3 2023 Added 22.65%
REPL Replimune Group, Inc.	$512M	$33,000 0.0% of portfolio	2,712	Q3 2024 New
EYPT Eye Point Pharmaceuticals, Inc.	$199M	$31,000 0.0% of portfolio	4,214	Q3 2024 New
ERAS Erasca, Inc.	$186M	$30,000 0.0% of portfolio	11,916	Q3 2024 New
ENTA Enanta Pharmaceuticals Inc	$118M	$27,000 0.0% of portfolio	4,658	Q3 2023 Reduced 94.68%
RLAY Relay Therapeutics, Inc.	$315M	$24,000 0.0% of portfolio	5,888	Q3 2023 Reduced 82.71%
ALLO Allogene Therapeutics, Inc.	$223M	$21,000 0.0% of portfolio	9,921	Q3 2024 Added 5.1%
SANA Sana Biotechnology, Inc.	$325M	$21,000 0.0% of portfolio	13,054	Q3 2024 New
COGT Cogent Biosciences, Inc.	$426M	$17,000 0.0% of portfolio	2,198	Q3 2024 New
ALEC Alector, Inc.	$107M	$15,000 0.0% of portfolio	7,914	Q3 2023 Added 40.29%
CGEM Cullinan Oncology, Inc.	$366M	$14,000 0.0% of portfolio	1,150	Q3 2024 New
IBRX Immunity Bio, Inc.	$1.26B	$14,000 0.0% of portfolio	5,517	Q3 2024 New
SAVA Cassava Sciences Inc	$66.2M	$13,000 0.0% of portfolio	5,361	Q3 2023 Reduced 48.17%
HUMA Humacyte, Inc.	$202M	$11,000 0.0% of portfolio	2,083	Q3 2024 New
JANX Janux Therapeutics, Inc.	$1.21B	$9,000 0.0% of portfolio	172	Q3 2024 New
PHAT Phathom Pharmaceuticals, Inc.	$259M	$7,000 0.0% of portfolio	840	Q3 2024 New
ALT Altimmune, Inc.	$261M	$4,000 0.0% of portfolio	552	Q3 2024 New
FDMT 4 D Molecular Therapeutics, Inc.	$118M	$1,000 0.0% of portfolio	120	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Public Employees Retirement Association Of Colorado, based on Form 13F filings with the SEC.

News

Stay updated on Public Employees Retirement Association Of Colorado with notifications on news.